

Margaret K Hahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1861487/publications.pdf>

Version: 2024-02-01

96
papers

3,046
citations

201674

27
h-index

189892

50
g-index

100
all docs

100
docs citations

100
times ranked

3946
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. <i>Neuropsychopharmacology</i> , 2022, 47, 664-672.	5.4	19
2	Technology-enabled collaborative care for youth with early psychosis: Results of a feasibility study to improve physical health behaviours. <i>Microbial Biotechnology</i> , 2022, 16, 1143-1151.	1.7	6
3	Schizophrenia: a disorder of broken brain bioenergetics. <i>Molecular Psychiatry</i> , 2022, 27, 2393-2404.	7.9	26
4	Effect of Antipsychotics on Glucose Sensing by the Brain. <i>Biological Psychiatry</i> , 2022, 91, S73.	1.3	0
5	P560. Impaired Obesity Awareness May Be Related to Interhemispheric Imbalance in the Posterior Parietal Areas. <i>Biological Psychiatry</i> , 2022, 91, S315-S316.	1.3	0
6	P97. Outcomes and Clinical Implications of Intranasal Insulin on Cognition and Brain Function in Humans: A Systematic Review and Meta-Analysis. <i>Biological Psychiatry</i> , 2022, 91, S126.	1.3	0
7	Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycaemia in mice. <i>Journal of Physiology</i> , 2022, 600, 2713-2728.	2.9	7
8	P530. Use of Metformin for the Prevention of Clozapine-Induced Weight Gain: A Retrospective Chart Review Study. <i>Biological Psychiatry</i> , 2022, 91, S303.	1.3	0
9	P544. Glucose Dysregulation in Antipsychotic-Na ⁺ -ve First Episode Psychosis Patients: In Silico Exploration of Gene Expression Signatures. <i>Biological Psychiatry</i> , 2022, 91, S308-S309.	1.3	0
10	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210965.	2.7	17
11	Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 190-200.	4.5	5
12	Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. <i>Psychiatry Research</i> , 2022, 314, 114680.	3.3	3
13	<scp>Technology-enabled</scp> collaborative care for youth with early psychosis: A protocol for a feasibility study to improve physical health behaviours. <i>Microbial Biotechnology</i> , 2021, 15, 828-836.	1.7	10
14	The Effect of Peer Support on Knowledge and Self-Efficacy in Weight Management: A Prospective Clinical Trial in a Mental Health Setting. <i>Community Mental Health Journal</i> , 2021, 57, 979-984.	2.0	3
15	Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. <i>Scientific Reports</i> , 2021, 11, 2004.	3.3	8
16	Olanzapine-induced insulin resistance may occur via attenuation of central KATP channel-activation. <i>Schizophrenia Research</i> , 2021, 228, 112-117.	2.0	5
17	Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 642403.	2.6	15
18	The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. <i>Nutrients</i> , 2021, 13, 1152.	4.1	25

#	ARTICLE	IF	CITATIONS
19	Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. <i>Behavioural Brain Research</i> , 2021, 402, 113101.	2.2	28
20	Direct and indirect control of hepatic glucose production by insulin. <i>Cell Metabolism</i> , 2021, 33, 709-720.	16.2	61
21	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. <i>NPJ Schizophrenia</i> , 2021, 7, 22.	3.6	35
22	Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. <i>Translational Psychiatry</i> , 2021, 11, 219.	4.8	14
23	Schizophrenia: Antipsychotics and drug development. <i>Behavioural Brain Research</i> , 2021, 414, 113507.	2.2	13
24	Adiposity in schizophrenia: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 524-536.	4.5	19
25	Editorial: Cardiovascular and Physical Health in Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2021, 12, 760250.	2.6	1
26	Brain insulin action in schizophrenia: Something borrowed and something new. <i>Neuropharmacology</i> , 2020, 163, 107633.	4.1	31
27	Brain insulin action: Implications for the treatment of schizophrenia. <i>Neuropharmacology</i> , 2020, 168, 107655.	4.1	19
28	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. <i>Neuropsychobiology</i> , 2020, 79, 5-12.	1.9	11
29	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	3.2	34
30	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 43-57.	2.4	33
31	Obesity in adults: a clinical practice guideline. <i>Cmaj</i> , 2020, 192, E875-E891.	2.0	592
32	Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. <i>Nutrients</i> , 2020, 12, 3883.	4.1	15
33	Mortality Risk Following Acute Coronary Syndrome Among Patients With Schizophrenia Spectrum Disorders—Addressing the Gaps. <i>Schizophrenia Bulletin</i> , 2020, 46, 743-744.	4.3	0
34	Identifying contexts and mechanisms in multiple behavior change interventions affecting smoking cessation success: a rapid realist review. <i>BMC Public Health</i> , 2020, 20, 918.	2.9	22
35	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , 2020, 124, 151-158.	3.1	31
36	Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study. <i>Biological Psychiatry</i> , 2020, 87, S414.	1.3	0

#	ARTICLE	IF	CITATIONS
37	A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update. <i>Biological Psychiatry</i> , 2020, 87, S357.	1.3	0
38	Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies. <i>General Hospital Psychiatry</i> , 2020, 66, 30-33.	2.4	46
39	Impact of a Web-Based Clinical Decision Support System to Assist Practitioners in Addressing Physical Activity and/or Healthy Eating for Smoking Cessation Treatment: Protocol for a Hybrid Type I Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e19157.	1.0	8
40	Antipsychotics and glucose metabolism: how brain and body collide. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E1-E15.	3.5	54
41	Understanding Engagement with a Physical Health Service: A Qualitative Study of Patients with Severe Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 872-880.	1.9	24
42	Female mice are protected against acute olanzapine-induced hyperglycemia. <i>Psychoneuroendocrinology</i> , 2019, 110, 104413.	2.7	18
43	Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons. <i>Psychoneuroendocrinology</i> , 2019, 109, 104400.	2.7	15
44	Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1149-1160.	2.4	38
45	AMPK β 1 activation suppresses antipsychotic-induced hyperglycemia in mice. <i>FASEB Journal</i> , 2019, 33, 14010-14021.	0.5	18
46	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	2.0	32
47	Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. <i>Psychoneuroendocrinology</i> , 2019, 104, 42-48.	2.7	33
48	52. Antipsychotics Perturb Glucose Homeostasis by Inhibiting Hypothalamic KATP Channel Activation. <i>Biological Psychiatry</i> , 2019, 85, S21-S22.	1.3	0
49	Pharmacological interventions for reduction of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	2.8	0
50	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	2.8	0
51	S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study. <i>Biological Psychiatry</i> , 2019, 85, S368-S369.	1.3	0
52	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
53	Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism. <i>Journal of Psychiatry and Brain Science</i> , 2019, 4, .	0.5	19
54	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6

#	ARTICLE	IF	CITATIONS
55	The effects of interventions targeting multiple health behaviors on smoking cessation outcomes: a rapid realist review protocol. <i>Systematic Reviews</i> , 2018, 7, 38.	5.3	4
56	Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. <i>Microbial Biotechnology</i> , 2018, 12, 1038-1044.	1.7	16
57	The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 3-15.	3.2	67
58	O10.6. OLANZAPINE IMPAIRS CENTRAL INSULIN ACTION: EFFECTS ON BODY FUEL PREFERENCE IN RATS. <i>Schizophrenia Bulletin</i> , 2018, 44, S104-S105.	4.3	2
59	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	2.6	115
60	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
61	Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. <i>Psychoneuroendocrinology</i> , 2018, 98, 127-130.	2.7	6
62	Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. <i>Human Psychopharmacology</i> , 2017, 32, e2631.	1.5	25
63	61. Olanzapine Inhibits Central Insulin Action Resulting in Glucose Dysregulation. <i>Biological Psychiatry</i> , 2017, 81, S25-S26.	1.3	1
64	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 317-335.	6.1	31
65	In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 424-431.	2.4	26
66	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , 2017, 11, 741.	2.8	78
67	Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1193-1203.	2.4	60
68	Atypical antipsychotics and effects on feeding: from mice to men. <i>Psychopharmacology</i> , 2016, 233, 2629-2653.	3.1	38
69	Treating Negative Symptoms in Schizophrenia: an Update. <i>Current Treatment Options in Psychiatry</i> , 2016, 3, 133-150.	1.9	123
70	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
71	An Overview of Links Between Obesity and Mental Health. <i>Current Obesity Reports</i> , 2015, 4, 303-310.	8.4	212
72	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. <i>Medical Hypotheses</i> , 2015, 85, 391-396.	1.5	11

#	ARTICLE	IF	CITATIONS
73	Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. <i>Journal of Endocrinology</i> , 2015, 227, 71-81.	2.6	25
74	What does schizophrenia teach us about antipsychotics?. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S14-8.	1.9	5
75	Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, E1-E2.	2.4	2
76	The neurobiology of relapse in schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 381-390.	2.0	30
77	Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly. <i>Drugs and Aging</i> , 2014, 31, 159-184.	2.7	14
78	Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model. <i>European Neuropsychopharmacology</i> , 2014, 24, 448-458.	0.7	18
79	Atypical antipsychotics and diabetic ketoacidosis: a review. <i>Psychopharmacology</i> , 2013, 226, 1-12.	3.1	45
80	Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: An animal model. <i>Schizophrenia Research</i> , 2013, 146, 162-169.	2.0	28
81	Risk of neutropenia in a clozapine-treated elderly population. <i>Schizophrenia Research</i> , 2013, 148, 183-185.	2.0	12
82	Chronic olanzapine administration in rats: Effect of route of administration on weight, food intake and body composition. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 103, 717-722.	2.9	19
83	Clozapine's Role in the Treatment of First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2013, 170, 146-151.	7.2	59
84	Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 740-746.	1.4	67
85	Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 11-17.	1.4	44
86	Behavioural interventions for reducing weight gain in schizophrenia. <i>The Cochrane Library</i> , 2013, . .	2.8	1
87	Examining Levels of Antipsychotic Adherence to Better Understand Nonadherence. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 261-263.	1.4	19
88	Topiramate in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 186-196.	1.4	21
89	Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model. <i>Schizophrenia Research</i> , 2011, 131, 90-95.	2.0	67
90	Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 86-89.	2.9	11

#	ARTICLE	IF	CITATIONS
91	Topiramate Augmentation in Clozapine-Treated Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 706-710.	1.4	33
92	Comment: Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychoticâ€“Induced Weight Gain. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1349-1350.	1.9	0
93	Rapid cycling bipolar disorders in primary and tertiary care treated patients. <i>Bipolar Disorders</i> , 2008, 10, 495-502.	1.9	26
94	Psychosis Induced by Low-Dose Bupropion: Sensitization of Dopaminergic System by Past Cocaine Abuse?. <i>Journal of Psychiatric Practice</i> , 2007, 13, 336-338.	0.7	11
95	Membrane topology and sequence requirements for oil body targeting of oleosin. <i>Plant Journal</i> , 2004, 37, 461-470.	5.7	59
96	Pharmacological interventions for reducing weight gain in schizophrenia. <i>The Cochrane Library</i> , 0, , .	2.8	4